Press Release

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPC IN

Lupin and MCGM Unite to launch Anti-TB Campaign in Mumbai

Covering 24 wards focusing on high-risk population across Mumbai, this will be one of the largest active-case-finding campaigns in India

Mumbai, June 29, 2018: Pharma major Lupin, a pioneer in the fight against Tuberculosis (TB), along with the Municipal Corporation of Greater Mumbai (MCGM) today announced a joint campaign to detect and address active cases of TB in Mumbai. The door-to-door Active Case Finding (ACF) campaign will cover all high-risk population areas selected from all 24 wards under the MCGM.

A contagious and airborne disease, TB ranks as the 2nd leading cause of death from a single infectious agent, after the Human Immunodeficiency Virus (HIV). The incidence of TB has been steadily increasing in the country, with India having the highest burden of TB in the world; an estimated 28 lakh cases annually, which accounts for one fourth of the global incidence of the disease. This results in almost 500,000 Indians losing their lives to TB each year. This is further compounded by a lack of awareness, which in turn leads to delay in the commencement of treatment. One of the main hurdles for TB eradication is the inability to detect all active cases from the community. There is a growing need to identify undetected cases from the community to prevent covert transmission.

This campaign and the methodology of execution follows the success of the Active Case Finding (ACF) pilot that was conducted by Lupin along with the TB department of the MCGM in 2017. The new 12-month project will involve comprehensive end-to-end TB detection, treatment and follow-up with door-to-door visits conducted in high-risk areas to identify symptomatic patients.

Speaking at the launch of this campaign, **Mr. Nilesh Gupta, Managing Director, Lupin** said, "With a high rate of prevalence and resultant mortality, TB has reached epidemic proportions impacting especially underprivileged sections of the community. As a global leader in anti-TB medicines, we have concentrated our energies in combatting TB for nearly five decades. As part of Dr. Desh Bandhu Gupta's vision to address areas of high national priority, we would like to extend our responsibility beyond research, manufacture, supply and marketing of TB drugs to create community outreach programs of the type we are launching today. Our partnership with MCGM is aligned with the national mission of making India TB-free by 2025 and this step will help move in the right direction towards a TB-free Mumbai."

The project will enlist the services of over 3,000 Community Health Volunteers (CHVs) of the TB department of MCGM, who will be imparted special training for this project. The efforts of the CHVs will be further supported by volunteers for facilitating the effective diagnosis of suspected patients and delivering their test results, arranging for treatment with the Revised National Tuberculosis Control Programme (RNTCP), and following the outcome of each individual case to closure.

Press Release

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPC IN

Commenting on the partnership **Dr. Padmaja Keskar, Executive Health Officer, MCGM** said, "Great things can be achieved if the public and private sector in India collaborate to resolve major issues faced by the nation. Through this partnership with Lupin, it would be possible to reach out to unidentified patients of TB in the community and treat them effectively. This initiative will adopt a door-to-door approach for a 12-month period and intends to cover all high-risk population in Mumbai."

Lupin is the world's largest manufacturer of anti-TB drugs and has been active in this space for 50 years. In 2016, Lupin developed a new approach for finding active cases of TB that was piloted in Mumbai between 2016 and 2017, and covered a population of over 21 lakh. The pilot conducted in 5 wards of the MCGM, involved deployment of an ecosystem of partner NGOs and community workers who made door-to-door visits, facilitated testing to verify positive cases and ensured follow-ups for treatment.

About Lupin Limited

Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally. The Company is a significant player in the Cardiovascular, Diabetology, Asthma, Pediatric, CNS, GI, Anti-Infective and NSAID space and holds global leadership position in the Anti-TB segment.

Lupin is the 12th and 8th largest generics pharmaceutical company by market capitalization (31st March 2018, Bloomberg) and revenues (31st Mar 2018, Bloomberg LTM) respectively. The Company is the 4th largest pharmaceutical player in the US by prescriptions (IQVIA MAT March 2018); 3rd largest Indian pharmaceutical company by global revenues (31st Mar 2018, Bloomberg LTM); 6th largest generic pharmaceutical player in Japan and 5th largest company in the Indian Pharmaceutical Market (IQVIA MAT March 2018).

For the financial year ended 31st March, 2018, Lupin's Consolidated sales and Net profits were at Rs. 155,598 million (USD 2.41 billion) and Rs. 2,513 million (USD 39 million) respectively. Please visit http://www.lupin.com for more information. You could also follow us on Twitter – www.twitter.com/lupinglobal

CIN: L24100MH1983PLC029442 Registered Office: Lupin Ltd, 3rd Floor, Kalpataru Inspire, Off Western Express Highway, Santacruz (East), Mumbai 400 055.

For further information or queries, please contact –

Pooja Thakran
VP – Corporate Communications
Email: poojathakran@lupin.com
Ph: +91-22-66402531 / 8291013225

Press Release

BSE: 500257 NSE: LUPIN REUTERS: LUPIN.BO BLOOMBERG: LPC IN

Arvind Bothra
Head – Investor Relations
Email: arvindbothra@lupin.com
Ph: +91-22-66402137